In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on CureVac ( CVAC – Research Report ), with a price target of $18.00. Roy Buchanan has given his Buy rating due to a combination of factors that suggest a positive outlook for CureVac’s future financial performance and operational advancements.
Should you invest in CureVac in Q4 2025?
Its cash runway is expected into Q4 of 2025 because of all the cost-cutting measures it has been able to achieve. There are several risks that investors should be aware of before investing in CureVac. The first risk to consider would be regarding the development of the avian influenza [H5N1] vaccine with GlaxoSmithKline.
Will CureVac partner with GlaxoSmithKline?
The ability for CureVac to partner with GlaxoSmithKline is based on a long-term partnership starting back in July 2020. The goal was for both companies to jointly use CureVac's mRNA technology to develop new products for infectious disease targets.
